NEWS

NEWS 2021.6.23 Exhibiting at Arab Health 2021

Professor Hiroshi Kawamoto’s laboratory, Kyoto University, is now making an exhibition of its r...

READ MORE
NEWS 2021.6.8 Our research activity to develop a new T cell therapy for COVID-19 was introduced in the TV program “Hodo Station”

Professor Hiroshi Kawamoto, a director of Rebirthel and the Vice Director of Institute for Fron...

READ MORE
NEWS 2021.5.15 Professor Hiroshi Kawamoto’s research was featured on Sankei Shimbun (Japanese newspaper)

In the evening edition of Sankei Shimbun on May 15th, 2021, Professor Hiroshi Kawamoto’s resear...

READ MORE
NEWS 2021.3.4 The article introducing Rebirthel was published in the web magazine “Nikkei Biotechnology & Business”

Nikkei Biotechnology & Business is the leading news site of biotechnology in Japan. In its ...

READ MORE
NEWS 2020.12.11 Our R&D activity to develop a new T cell therapy for the novel coronavirus infection was introduced on Japanese TV program.

Professor Hiroshi Kawamoto, an excecutive director of Rebirthel, is recently conducting the col...

READ MORE
NEWS 2020.10.15 Collaborative research project between Rebirthel and Fujita Health University – On-side visit video

This video was taken when our executive director, Hiroshi Kawamoto (Professor, Institute for Fr...

READ MORE
NEWS 2020.10.14 Rebirthel concluded the research collaboration agreement with Fujita Health University. – Joint development of the therapy for the novel coronavirus infection using universal killer T cells –

Rebirthel Co., Ltd. concluded an agreement to collaborate with Fujita Health University to deve...

READ MORE
NEWS 2020.10.1 Rebirthel concluded the research license agreement with Otsuka Pharmaceutical.

Rebirthel Co., Ltd. (hereafter Rebirthel) concluded the research license agreement with Otsuka ...

READ MORE
NEWS 2020.4.9 Introduction

The world is presently facing the serious situation of the coronavirus pandemic. We all need to...

READ MORE